The Chromosomal Microarray Analysis (CMA) Testing Market size was valued at USD 1.2 Billion in 2022 and is projected to reach USD 2.5 Billion by 2030, growing at a CAGR of 10.1% from 2024 to 2030.

Microarray-based comparative genomic hybridization (CGH microarray) is an evolving technology for the rapid multiplex detection of genomic imbalances. 1 This diagnostic strategy has contributed to our ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray (CMA) as the new standard practice for genetic evaluation of children with ...

The Europe Chromosomal Microarray (Cma) Testing Market, valued at 9.28 billion in 2025, is anticipated to advance at a CAGR of 13.33% during 2026–2033, reaching 19.66 billion by 2033 as adoption grows ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray as the new standard practice for genetic evaluation of children with unexplained ...

CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

A new test may be better at detecting potentially harmful genetic changes in children before they are born than current methods, researchers say. The test, called a chromosomal microarray, detected ...

Current serological immunoassays have inherent limitations for certain infectious diseases such as Lyme disease, a bacterial infection caused by Borrelia burgdorferi in North America. Here we report a ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

JA Rosenfeld is an employee of Signature Genomic Laboratories, a subsidiary of PerkinElmer, Inc. The authors have no other relevant affiliations or financial involvement with any organization or ...

A new method of prenatal testing that can detect more genetic problems in a fetus than ever before could be headed toward wider use after encouraging results from a clinical trial, researchers said.